Health activists and Cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...
More »SEARCH RESULT
Doc panel for drug approval
-The Telegraph The Centre today asked a panel of doctors to outline measures to improve drug approval procedures, three days after a parliamentary standing committee said India’s drug regulators had broken laws, ignoring the interests of patients. The panel announced by the Union health ministry has been asked to suggest steps to improve the procedural aspects of the Central Drugs Standards Control Organisation (CDSCO), the agency entrusted with approving medicines for sale...
More »Bayer to challenge Cipla’s decision to cut price of cancer drug
-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...
More »Cipla shocks rivals by slashing cancer drug prices up to 75%-Divya Rajagopal
Fighting cancer has just become less expensive for millions of Indian patients. More than 12 years after he electrified the pharma industry by taking on powerful global giants in his quest to supply cheap anti-AIDS drugs, Cipla promoter YK Hamied is back donning the role of a price warrior. This time, his attention is on anti-cancer drugs. On Thursday, Cipla cut prices of key cancer drugs by nearly 75%, an astounding,...
More »Glaring gender bias ails heart health-Kounteya Sinha
Women in India face discrimination even when it comes to their heart health. Three separate studies - one of them from India and the other two from China and West Asia - presented at the World Congress of Cardiology in Dubai on Friday said that women don't receive the same treatment as men for heart disease across the world. They said that women with acute coronary syndrome (ACS) receive inferior or less...
More »